Please ensure Javascript is enabled for purposes of website accessibility

Here's an Up-and-Coming Biotech Stock to Watch With a Cannabis Connection

By Keith Speights and Brian Orelli, PhD – Oct 2, 2021 at 6:10AM

Key Points

  • Ginkgo Bioworks recently began trading publicly under the ticker DNA.
  • The company focuses on synthetic biology.
  • Ginkgo is developing a wide range of products, including high-quality cannabinoids.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

And it has a really great ticker that many other biotechs might envy.

There aren't many biotechs that have research underway targeting the development of cannabinoids. One of them is Ginkgo Bioworks (DNA 0.54%), which recently went public through a merger with a special purpose acquisition company. In this Motley Fool Live video recorded on Sept. 22, 2021, Motley Fool contributors Keith Speights and Brian Orelli answer a viewer's question about this biotech with a cannabis connection.

10 stocks we like better than Ginkgo Bioworks Holdings, Inc.
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and Ginkgo Bioworks Holdings, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks


*Stock Advisor returns as of September 17, 2021


Keith Speights: Grant asks, "What do you know about DNA? Great ticker, surprised it was available."

Brian Orelli: Yeah. This was the old Genentech ticker. Genentech the ticker was DNA and then it got acquired twice by Roche. But eventually, it got fully acquired and taken over by Roche. It got acquired by Roche, and spun out, and then reacquired by Roche. That's why the ticker DNA was available because nobody took it over after Roche. This is Ginkgo Bio something that technology, I can't remember the rest of the-

Speights: BioWorks, I think.

Orelli: Yeah, BioWorks. I knew it was in biotechnology, but I couldn't come up with it. This is a synthetic bio company. I think the biggest worry with synthetic biotech is that you have to understand both, how can they make the drug or the product, which often isn't drugs. But then you also have to understand their potential for the products that they're making.

I think that's really the difficulty with synthetic biotech companies, as you have to understand both the science, but you also need to understand the potential for their products which may be completely unrelated to biotechs.

I think we saw one earlier this year that failed and it was developing a coating for foldable screens for phones. If you don't understand the market for foldable sweet screens, then you can't really understand what the potential of the company is.

Speights: For those of you who follow the cannabis space, Ginkgo also has its toes in the water in cannabis. I think it's working with Cronos Group (CRON 0.66%), which is a Canadian cannabis producer, to develop basically cannabinoids using fermentation processes. Healthcare and cannabis, interesting stock. Like Grant said, they managed to get hold of a really great ticker to use.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ginkgo Bioworks Holdings, Inc. Stock Quote
Ginkgo Bioworks Holdings, Inc.
$1.85 (0.54%) $0.01
Cronos Group Inc. Stock Quote
Cronos Group Inc.
$3.03 (0.66%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.